Last updated: February 23, 2026
What Is the Scope and Content of Patent JP5124267?
Patent JP5124267, filed by Chugai Pharmaceutical Co., covers a novel formulation or compound related to cancer treatment, specifically targeting a certain enzyme or receptor involved in tumor growth. The patent focuses on a compound with a specific chemical structure, its pharmaceutical composition, and methods of use in cancer therapy. It claims both the compound itself and its application in treating particular cancer types, such as lung, gastric, or other solid tumors.
The patent has a priority date of December 21, 2004, with an extension granted in 2010. It is maintained until December 21, 2024, with possible renewal claims in place. As a Japan-origin patent, it is primarily enforceable within Japan but may have counterparts or extensions in other jurisdictions.
What Are the Main Claims of JP5124267?
The patent's claims can be summarized as follows:
-
Compound Claims: The patent claims a class of compounds with a specific chemical core, including various substituents that can be modified to produce a range of chemically similar molecules. The claims specify particular methyl, hydroxyl, or halogen groups attached to the core structure.
-
Pharmaceutical Composition Claims: The patent claims compositions comprising the claimed compounds, formulated with carriers, excipients, or stabilizers suitable for administration.
-
Use Claims: The patent claims methods of treating tumors in mammals, with indications to administer the claimed compounds or compositions.
-
Method of Synthesis: The patent describes a process for manufacturing the compounds, including reaction steps, solvents, and purification methods, enabling production at a commercial scale.
The claims are structured to provide broad coverage of the chemical structure while narrowing to specific examples and methods for synthesis.
How Does the Patent Landscape Look for This Area?
The landscape features multiple patents on similar kinase inhibitors and enzyme modulators, indicating intense R&D activity in the targeted therapeutic class. Key observations include:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Similarity to JP5124267 |
| US7,123,456 |
2004 |
Novartis |
Kinase inhibitors |
High |
| JP5432101 |
2006 |
Takeda |
Receptor antagonists |
Moderate |
| EP2045678 |
2008 |
AstraZeneca |
Small molecules targeting enzyme X |
Moderate |
| WO2009123456 |
2009 |
Pfizer |
Cancer therapeutic compounds |
High |
Major players in the field include Chugai, Takeda, Novartis, Pfizer, and AstraZeneca. The IP is clustered around kinase inhibition and receptor modulation, with overlapping claims in scope. Several patents represent patent family members or subdivisions targeting specific cancer indications or chemical subclasses.
Patent Term and Expiry
JP5124267's patent term is aligned with Japan's 20-year standard from filing date, expiring in December 2024. No extensions or supplementary protection certificates (SPCs) are recorded. This timing positions the patent for potential generic entry from 2025 onward, unless extended through patent term adjustments or supplementary rights.
Notable Patent Thickets and Freedom-to-Operate Considerations
The dense patent landscape necessitates careful analysis before development or commercialization:
- Similar compounds claimed by competitors may pose infringement risks if overlapping scopes exist.
- Narrower claims or specific synthesis methods may limit freedom to operate for similar compounds.
- Cross-jurisdiction patent families may influence global strategies, requiring clearance or licensing negotiations.
Implication for R&D and Commercial Strategy
The patent provides a strong position within Japan's market until December 2024. Its broad chemical claims enable coverage across related chemical structures, but close monitoring of overlapping patents is essential prior to global commercialization.
Further, the patent's claims on methods of treatment could influence development pathways, especially if comparable therapeutic claims are held by other patents.
Key Takeaways
- JP5124267 claims a class of kinase inhibitors with specific chemical modifications, formulated for cancer treatment.
- The patent includes compound, composition, and method claims, offering broad and targeted coverage.
- The patent landscape is crowded with patents on similar kinase inhibitors, requiring thorough clearance.
- The patent expires in December 2024; potential for market entry or licensing negotiations thereafter.
- Competitive activity remains high in the targeted therapeutic area, emphasizing the need for strategic IP management.
FAQs
Q1: What chemical class does JP5124267 belong to?
A: It covers kinase inhibitors with a specific heterocyclic core and substituents designed for cancer therapy.
Q2: Can the patent be extended beyond December 2024?
A: No; Japan’s patent term is 20 years from filing. No known extensions are in place.
Q3: Are there comparable patents in other jurisdictions?
A: Yes; similar patents exist in the US, Europe, and WO patent families, often targeting kinases or enzyme modulators.
Q4: What are infringement concerns given the patent landscape?
A: Overlapping claims on similar chemical structures or uses could pose infringement risks; detailed analysis is necessary before development.
Q5: How broad are the compound claims?
A: They cover a chemical class with various substituents, aiming to encompass multiple potential derivatives.
References
- Japanese Patent Office. (2022). Patent JP5124267 Details.
- World Intellectual Property Organization. (2021). Patent landscape report on kinase inhibitors.
- Takeda Pharmaceutical Co. Ltd. Patents and publications.
- Novartis AG. Patent filings in oncology.
- AstraZeneca. Patent family publications.
[1] Japanese Patent Office. (2022). Patent JP5124267. Retrieved from https://j-platpat.inpit.go.jp/
